Sotagliflozin, a dual sodium‐glucose co‐transporter‐1 and sodium‐glucose co‐transporter‐2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes
Diabetes, Obesity and Metabolism · 2023
DOI: 10.1111/dom.15047 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Elisabeth B Stougaard und 6 weiteren Autor:innen. Beteiligte Einrichtung: Complication Research, Steno Diabetes Center Copenhagen, Herlev, Denmark. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Kidney Diseases. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Sotagliflozin (SOTA) as adjunct to insulin therapy improves glycemic control, reduces body weight and blood pressure, and increases time in range in adults with type 1 diabetes (T1D). SOTA demonstrated CV and kidney benefits in high‐risk adults with type 2 diabetes. These potential benefits using SOTA for T1D may collectively outweigh the risk of diabetic ketoacidosis. The present analysis estimated the risk of CVD and kidney failure in adults with T1D treated with SOTA. Materials and Methods Participant‐level data were used from the inTandem trials evaluating 2980 adults with T1D randomized to once‐daily placebo, SOTA 200 mg, or SOTA 400 mg for 24 weeks. For each participant, the cumulative risks of developing CVD and kidney failure were estimated using the Steno T1 Risk Engine. A subgroup analysis was performed in participants with BMI ≥ 27 kg/m 2 .
Results
SOTA significantly reduced the predicted 5‐ and 10‐year CVD risk in the SOTA 200 and 400 mg pooled group with a relative change in the SOTA group compared to the relative change in the placebo group of (mean [95%‐confidence interval (CI)]) −6.6 (−7.9, −5.3) % and −6.4 (−7.6, −5.1) % ( p < 0.0001 for both) respectively. For the 5‐year ESKD risk there was a significant reduction with a relative change of −5.0 (−7.6, −2.3) % ( p = 0.0003). Similar results were observed with the individual doses and in participants with BMI ≥ 27 kg/m 2 .
Conclusion
This analysis provides additional clinical results that may positively balance the benefit/risk assessment of SGLT inhibition use in T1D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Complication Research, Steno Diabetes Center Copenhagen, Herlev, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Herlev, Denmark.
- Clinical Epidemiology, Steno Diabetes Center Copenhagen, Herlev, Denmark.
- Department of Public Health, University of Copenhagen, Herlev, Denmark.
- Lexicon Pharmaceuticals, Inc., The Woodlands, Texas, USA.
ORCID-Profile: Elisabeth B Stougaard, Peter Rossing
Zitieren
APA
Stougaard, E. B., Rossing, P., Vistisen, D., Banks, P., Girard, M., Davies, M. J., & Persson, F. (2023). Sotagliflozin, a dual sodium‐glucose co‐transporter‐1 and sodium‐glucose co‐transporter‐2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15047
Vancouver
Stougaard EB, Rossing P, Vistisen D, Banks P, Girard M, Davies MJ, et al. Sotagliflozin, a dual sodium‐glucose co‐transporter‐1 and sodium‐glucose co‐transporter‐2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes. Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.15047
BibTeX
@article{Stougaard2023,
author = {Stougaard, Elisabeth B and Rossing, Peter and Vistisen, Dorte and Banks, Phillip and Girard, Manon and Davies, Michael J and Persson, Frederik},
title = {Sotagliflozin, a dual sodium‐glucose co‐transporter‐1 and sodium‐glucose co‐transporter‐2 inhibitor, reduces the risk of cardiovascular and kidney disease, as assessed by the Steno T1 Risk Engine in adults with type 1 diabetes},
journal = {Diabetes, Obesity and Metabolism},
year = {2023},
doi = {10.1111/dom.15047}
}
EUVIMED